OBJECTIVE: To clarify the effective breakthrough point of roles which clinical pharmacists play in the clinical treatment. METHODS: Through clinical rounds, clinical pharmacists found that the combination between paroxetine and brain protein hydrolyzate may cause disruption. By searching a large number of documents, clinical pharmacists were informed that paroxetine was the P450 liver enzyme(CYP)2D6 inhibitors, which affected the brain protein hydrolyzate metabolism in vivo, causing adverse interaction. RESULTS: Clinical pharmacists proposed reasonable treatment options. After the physician adopted and implemented the program, the patient was discharged from hospital. CONCLUSION: In the clinical treatment, clinical pharmacists' entry point can be adverse reactions in the treatment, and also can be medication compliance in patients and so on.%目的:阐明临床药师在临床治疗中发挥作用的有效切入点.方法:临床药师通过临床查房,发现帕罗西汀与脑蛋白水解物联用存在潜在的相互作用,通过查阅大量资料,获知帕罗西汀为细胞色素P450酶(CYP)2D6抑制剂,影响了脑蛋白水解物在体内的代谢,引起不良的相互作用.结果:临床药师提出合理的治疗方案,医师采纳并实施方案后,患者康复出院.结论:临床药师在临床治疗的切入点可以是治疗中出现的不良反应,也可以是患者的用药依从性等其他方面.
展开▼
